Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 96% confidence The provided text is a Form 6-K filing by a foreign private issuer (XORTX Therapeutics Inc.) submitted to the U.S. SEC. It primarily serves as a compliance/regulatory report (attesting to the issuance of an attached press release) rather than presenting substantive financial statements or acting as an earnings release or other specialized report. Under the taxonomy, this falls into the General Regulatory Filings category (RNS).
2026-05-19 English
FORM 6-K
Regulatory Filings Classification · 10% confidence The document is a U.S. SEC Form 6-K, which is a regulatory submission by a foreign private issuer announcing attached exhibits (condensed interim financials, MD&A, and officer certificates) rather than containing the substantive interim financial statements in the body. Under the “menu vs. meal” rule, it is a short announcement that the report and certificates are attached, and per the certification rule, the SOC references to CEO/CFO certificates classify as a regulatory filing. Therefore, the correct classification is RNS (Regulatory Filings).
2026-05-18 English
424B4
Capital/Financing Update Classification · 85% confidence The document is a Securities and Exchange Commission (SEC) prospectus under Rule 424(b)(4) for an offering of common shares and pre-funded warrants by XORTX Therapeutics, detailing terms of the financing, plan of distribution, use of proceeds, risk factors, etc. It is not an earnings release, proxy statement, or annual report, but a detailed fundraising document (public offering prospectus) describing capital raising and issuance of new shares/warrants. This fits the definition of a Capital/Financing Update (CAP).
2026-05-15 English
FORM 6-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 6-K filing by a foreign private issuer. It contains no substantive financial statements or management discussion; it simply presents an SEC cover page, signature block, and indicates a press release (Exhibit 99.1) is attached. This is a generic regulatory submission rather than an Annual Report, interim report, earnings release, or detailed investor presentation. Under our taxonomy, standalone SEC forms and other compliance notices that don’t fit other categories default to Regulatory Filings (RNS).
2026-05-14 English
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1221 characters), and it primarily serves as a regulatory filing to disclose a press release. According to the rules, such filings that do not contain full reports or detailed financial data should be classified as Regulatory Filings (RNS).
2026-04-21 English
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1221 characters), and it primarily serves as a regulatory update with an attached press release. According to the rules, such filings that do not contain full financial reports or detailed analysis but serve as regulatory announcements fall under Regulatory Filings (RNS).
2026-04-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.